Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / 10-14 September 2007 1 |1 | Prequalification programme:

Slides:



Advertisements
Similar presentations
PHARMACOKINETIC.
Advertisements

Bioequivalence Studies Anoop Agarwal
III. Drug Metabolism  The aim of drug metabolism is to convert lipid soluble (non polar) drugs to polar metabolites easily excreted in urine.  The liver.
Pharmacokinetics as a Tool
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence.
Selected bioavailability and pharmacokinetic calculations Dr. Osama A. A. Ahmed.
Pharmacokinetics of Drug Absorption
Dale P. Conner, Pharm.D. Division of Bioequivalence OGD, CDER, FDA
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Regulatory Requirements.
ABSORPTION OF DRUGS DR.SOBAN SADIQ.
Hanoi, WORKSHOP ON PREQUALIFICATION OF ARV: BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence Study Design and Conduct Presented.
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Bioequivalence Studies Dr Sanet Aspinall, PhD Managing Director AddClin Research Pretoria 20 March 2009.
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Prequalification project Drs. Jan Welink. * Note to applicants on the choice of comparator products for the prequalification.
ERT 420 BIOPHARMACEUTICAL ENGINEERING ERT 420 BIOPHARMACEUTICAL ENGINEERING Semester 1 Academic Session 2012/2013 HUZAIRY HASSAN School Of Bioprocess Engineering.
Pharmacology Department
CLEARANCE (CL) describes the efficiency of irreversible elimination of a drug from the body by excretion of unchanged drug. Metabolic conversion of the.
Week 6- Bioavailability and Bioequivalence
Pharmacokinetics Introduction
Concepts and Applications of Pharmacokinetics
Regulatory requirements Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
ACPS Meeting, October 19-20, 2004 BioINequivalence: Concept and Definition Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs, OPS, CDER,
SYSTEMIC ABSORPTION AS THE MOST ACCURATE AND SENSITIVE METHOD OF DETERMINING BIOEQUIVALENCE OF GENERIC TOPICAL PRODUCTS Chris Hendy Ph.D. Novum Pharmaceutical.
Bioavailability Dr Mohammad Issa.
FARMAKOKINETIKA. INTRODUCTION Historically, pharmaceutical scientists have evaluated the relative drug availability to the body in vivo after giving a.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
Bioequivalence Dr Mohammad Issa Saleh.
1 Single-dose kinetics Plasma [Drug] curve Upon administration [drug] plasma reaches a max Then begins to decline as the Drug is eliminated Cp max = max.
WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.
Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
Pharmacology Department
BASIC BIOPHARMACEUTICS
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
Introduction What is a Biowaiver?
Pharmacology Department
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
Foundation Knowledge and Skills
In vitro - In vivo Correlation
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
By : Dr. Roshini Murugupillai
Definitions and Concepts
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Physiology for Engineers
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
Pharmacology I BMS 242 Lecture II (Continued)
Introduction What is a Biowaiver?
Applications of Pharmacokinetics
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Quantitative Pharmacokinetics
Pharmacology I BMS 242 Lecture II (Continued)
Pharmacokinetics & pharmacodynamcs
Selected Bioavailability and Pharmacokinetic Calculations
Bioequivalence trials: design, evaluation, regulatory requirements
Presentation transcript:

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme: Priority essential medicines Training Workshop for evaluators from National Medicines Regulatory Authorities in the East African Community: Evaluation of quality and interchangeability of medicinal products. Dar Es Salaam United Republic of Tanzania 10 – 14 September 2007

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |2 | Training Workshop on Evaluation of quality and interchangeability of medicinal products. Bioavailability versus bioequivalence Presenter: Drs. J. Welink Senior pharmacokineticist Medicines Evaluation Board, NL WHO adviser

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |3 | Absorption Pharmacokinetics Describe the transport processes of drugs throughout the body

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |4 | Absorption Pharmacokinetics Use mathematical models to describe: Absorption Distribution Metabolism Excretion dA/dt = dAa/dt – k.A

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |5 | Kinetics The Kinetic Concept receptor drug effect

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |6 | Kinetics The Kinetic Concept receptor drug concentration effect absorption distributionelimination

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |7 | Kinetics The Kinetic Concept absorption dissolution disintegration bioavailability

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |8 | Bioavailability Bioavailability describes the fraction of the the dose of a drug that enters into the systemic circulation.

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |9 | Bioavailability Bioavailability means the rate and extent to which the active substance or therapeutic moiety is absorbed from a pharmaceutical form and becomes available at the site of action. plasma

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioavailability Evaluation of bioavailability in vivo: extent (and rate) of absorption relative bioavailability

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioavailability oral / i.v. mass balance extent of absorption

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioavailability oral/i.v. absolute bioavailability Estimates the efficiency of absorption of the drug from the formulation versus an intravenous bolus injection F = AUC oral / AUC iv

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioavailability mass balance study radio labeled drug Recovery: - expired air - feaces - urine Urine: intact = at least abs. bioavailability Feaces: intact = may be not absorbed………

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioavailability relative bioavailability absolute bioequivalence food-effect different formulations interactions

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioavailability Relative bioavailability food effect: no change in absorption: delay in absorption: increase in absorption: decrease in absorption:

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioavailability Interactions: Absorption Distribution Metabolism Excretion food effect inhibition protein-binding displacement induction decrease increase

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioavailability Relative bioavailability diff. formulations:

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioequivalence Pharmaceutical equivalents: Medicinal products are pharmaceutical equivalents if they contain the same amount of the same active substance in the same dosage form that meet the same or comparable standard. Pharmaceutical alternatives: Medicinal products are pharmaceutical alternatives if they contain the same active moiety but differ in chemical form of that moiety or in the dosage form or strength.

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioequivalence Bioavailability Pharmaceutical equivalent Pharmaceutical alternatives

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioequivalence Bioequivalence: Two medicinal products are bioequivalent if they are pharmaceutical equivalents or alternatives and if their bioavailabilities (rate and extent) after administration in the same molar dose are similar to such degree that their effects, with respect to both efficacy and safety, will be essential the same.

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioequivalence Essential similar products: A proprietary medicinal product will be regarded as essential similar to another product if it has the same qualitative and quantitative composition in terms of active substances, and the pharmaceutical form is the same and, where necessary, bioequivalence with the first product has been demonstrated by appropriate bioavailability studies carried out.

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | Bioequivalence Bioequivalence: = bioavailability with pre-defined criteria for the rate and extent of absorption!!

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September | End